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Introduction: Maintenance therapy in advanced non–small-cell 
lung cancer (NSCLC) might lead to resistance to subsequent treat-
ments. IFCT–GFPC 0502 study showed a progression-free survival 
(PFS) benefit with gemcitabine or erlotinib maintenance compared 
with observation after cisplatin-gemcitabine chemotherapy. The trial 
included a pre-defined pemetrexed second-line therapy, allowing 
post-hoc assessment of its efficacy according to previous mainte-
nance treatment or treatment-free interval.
Methods: Stage IIIB/IV NSCLC patients were randomized after 
four cycles of cisplatin-gemcitabine chemotherapy to either observa-
tion or to receive maintenance therapy with gemcitabine or erlotinib. 
Pemetrexed was given as second-line treatment on disease progres-
sion in all arms. PFS and overall survival (OS) were assessed from 
the beginning of pemetrexed therapy according to randomization arm.
Results: Of the 464 randomized patients, 360 (78 %) received 
second-line pemetrexed (130 [84%], 114 [74%], and 116 [75%] in 
observation, gemcitabine, and erlotinib arm, respectively). Median 
number of pemetrexed cycles was 3 (1–40) in all arms. Median PFS 
did not differ between gemcitabine and observation arms (4.2 versus 
3.9 months, hazard ratio [HR] [95% confidence interval [CI] 0.81 
[0.62–1.06]) or between erlotinib and observation arms (4.2 versus 
3.9 months, HR 0.83 [0.64–1.09]). OS data showed a non-significant 
improvement with gemcitabine arm versus observation arm (8.3 ver-
sus 7.5 months, HR 0.81 [0.61−1.07]) or erlotinib arm versus obser-
vation arm (9.1 versus 7.5 months, HR 0.80 [0.61−1.05]). Results 
were similar for non-squamous patients. Grade 3 to 4 treatment-
related adverse events (AEs) were comparable in all arms.
Conclusions: Maintenance therapy with gemcitabine continuation 
or erlotinib does not seem to impair efficacy of second-line peme-
trexed comparatively to administration after a treatment-free interval.
Key Words: Maintenance, Pemetrexed, Non–Small-Cell Lung 
Cancer, Second line.
(J Thorac Oncol. 2013;8: 906-914)
Non–small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the world.1 Approximately 
40% of new lung cancers are diagnosed at the stage of 
metastatic disease. First line treatment of advanced NSCLC is 
based on platinum-doublet chemotherapy for most of patients, 
with a median overall survival (OS) of 10 to 13 months.2–6 
A key challenge is to improve the outcome of patients who 
have received adequate first-line therapy and have achieved at 
least stable disease. For these patients, maintenance therapy 
constitutes a strategic advance, defined as the continuation 
of an adapted treatment after the maximal response to 
“induction” chemotherapy has been obtained, to delay disease 
progression with the ultimate goal to prolong OS.7,8 There 
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are several ways to administer maintenance therapy: the first 
one is to continue with a targeted therapy initially used in 
combination with platinum-based induction chemotherapy, 
for example bevacizumab. The second one is to continue with 
the drug that has been combined to cis- or carboplatin during 
induction chemotherapy, called “continuation” maintenance. 
Another way is to immediately introduce a new treatment at 
the end of induction treatment, particularly one drug validated 
for second-line therapy such as docetaxel, pemetrexed or 
erlotinib. This strategy is usually called “switch” maintenance. 
Two drugs have been approved for maintenance therapy 
in advanced NSCLC: pemetrexed as either “switch” or 
“continuation” maintenance for patients with non-squamous 
carcinoma histology9–12 and erlotinib as “switch” maintenance 
in unselected patients, except for European countries in which 
approval has been restricted to patients with stable disease 
after induction chemotherapy.11,13–15
However, there are still unanswered questions about 
maintenance strategy, especially concerning the selection of 
patients who will benefit most from either “continuation “ 
maintenance or “ switch “ maintenance therapy. Another issue 
is the impact of maintenance therapy, in particular for “contin-
uation” maintenance, on the effectiveness of subsequent lines 
of treatment. Continuous exposure of tumor cells to mainte-
nance therapy in advanced NSCLC might lead to select tumor 
cell clones resistant to subsequent treatments.7,16–18
The Intergroupe Francophone de Cancérologie 
Thoracique–Groupe Francais de Pneumo-Cancérologie 
(IFCT–GFPC) 0502 study showed a progression-free survival 
(PFS) benefit with gemcitabine continuation maintenance 
or erlotinib switch maintenance compared with observation 
after cisplatin-gemcitabine induction chemotherapy.11 This 
trial included a predefined second-line therapy with peme-
trexed, allowing post-hoc assessment of its efficacy and safety, 
according to previous maintenance treatment or treatment-
free interval. Since the study was designed before the inter-
action of pemetrexed with histology was known, we enrolled 
patients irrespective of histological subtype. The primary end 
point was PFS measured from the beginning of second-line 
pemetrexed therapy. Secondary end points included response 
rate, OS and tolerance to pemetrexed second-line therapy.
PATIENTS AND METHODS
Eligibility criteria included patients of IFCT–GFPC 
0502 study in whom disease progression (Response Evaluation 
Criteria In Solid Tumors version 1.0 [RECIST 1.0])19 had 
occurred under maintenance by gemcitabine or erlotinib, or 
in the observation arm. Enrolled patients were greater than 18 
years of age, with histologically or cytologically proven stage 
IIIB with pleural effusion or stage IV NSCLC and an Eastern 
Cooperative Oncology Group performance status of 0 or 1. 
Other inclusion criteria included: adequate renal (creatinine 
clearance >60 ml/mn), hepatic (bilirubin <20 micromol/l, ala-
nine transaminase or aspartate transaminase less than 2.5 × 
upper normal limit or less than 5 × upper normal limit in case 
of liver metastasis) and hematologic (absolute neutrophils 
count greater than 1.5 × 109/l and platelet count greater than 
100 × 109/l) functions, measurable disease per RECIST 1.0.19
Exclusion criteria included small cell or neuro- 
endocrine lung cancer, prior chemotherapy for NSCLC, 
symptomatic brain metastases; prior treatment with EGFR-
tyrosine kinase inhibitor; any concurrent radiotherapy, unless 
palliative localized bone radiotherapy; concomitant treatment 
with rifampicin, carbamazepine, phenobarbital, phenytoin, 
other serious comorbid conditions, such as congestive heart 
failure, unstable angina, significant arrhythmia or history of 
myocardial infarction in the 12 months preceding the trial 
entry, interstitial lung disease, uncontrolled infection status, 
use of non-steroid anti-inflammatory agents and second-line 
treatment other than pemetrexed.
The study was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice guide-
lines and approved by the institutional ethics committee from 
the Hospices civils de Lyon, sponsor of the trial. All patients 
signed written informed consent before treatment.
Study Design and Treatment
During the first part of the IFCT–GFPC 0502 study, 
induction chemotherapy consisted of gemcitabine 1,250 mg/
m2 (administered intravenously on days 1 and 8) plus cispla-
tin 80 mg/m2 (administered intravenously on day 1, every 21 
days) for a maximum of four cycles. Patients who demonstrated 
complete response, partial response, or stable disease were 
randomized to either observation, continuation maintenance 
with gemcitabine 1,250 mg/m2 (administered intravenously on 
days 1 and 8, every 21 days) or maintenance with oral erlotinib 
(150 mg/day). Randomization was stratified according to cen-
ter, gender, histology (adenocarcinoma/other), smoking status 
(current/former versus never), and response to cisplatin–gem-
citabine induction chemotherapy (objective response/stable dis-
ease) using a minimization adaptive randomization method. At 
the occurrence of disease progression, all patients were being 
proposed second-line chemotherapy with pemetrexed. Patients 
began taking oral folic acid supplement (350–1,000 μg/day) at 
least 7 days before the first dose of pemetrexed. Vitamin B
12
 
(1,000 μg) was given intramuscularly once within 7 days before 
the first dose and then every 9 weeks thereafter. Premedication 
with corticosteroids (equivalent to 4 mg of dexamethasone 
twice daily) was administered for three days starting the day 
before pemetrexed perfusion. Pemetrexed was administered by 
a 10 minutes intravenous perfusion the first day of each 21-day 
cycle. Subsequent treatments after second-line pemetrexed 
were selected at the discretion of each investigator.
Dose Modifications
During pemetrexed second-line therapy, patients 
experiencing a nadir platelets count lower than 50.109/l or a 
neutropenia less than 0.5 × 109/l required a 25% dose reduction 
of pemetrexed. If the neutrophil count was below 1.5 × 109/l 
or the platelet count was below 100.109/l on day 1 of any 
cycle, chemotherapy was postponed until recovery. Dose 
modifications for other grade 3 and 4 toxicities also consisted 
in a 25% dose reduction. Any reduction at a lower level 
dose was definitive (no subsequent re-increase in dose). The 
recurrence of grade 3 to 4 toxicity after two dose reductions 
led to definitive pemetrexed discontinuation.
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Assessments
Evaluations of the antitumor effect of second-line che-
motherapy were conducted in accordance with the habits of 
each center. Disease status was assessed according to RECIST 
1.0 by each investigator, without independent or panel review.19
Toxicity grading was performed according to the 
National Cancer Institute Common Toxicity Criteria for 
adverse events (AEs) (NCI-CTCAE), version 3.0.20
Statistical Methods
This is a post-hoc analysis of the effectiveness of peme-
trexed in second-line after either treatment-free interval or 
maintenance therapy with gemcitabine or erlotinib in IFCT–
GFPC 0502 phase III study. The primary end point is PFS, 
defined as the time from the beginning of pemetrexed to the 
time of documented disease progression or death, or censored 
at last follow-up for living patients. Secondary end points 
included tumor response assessed by investigators (RECIST 
1.0), OS, calculated from the date of beginning of pemetrexed 
to the date of death from any cause or to last follow-up for 
living patients (censured observation) and safety. Analysis 
restricted to the subgroup of patients with non-squamous cell 
carcinomas was also performed because of the lack of recog-
nized effectiveness to pemetrexed in squamous cell carcinoma.
Differences in survival estimates between arms were 
assessed using a two-sided log-rank test. PFS and OS were 
analyzed using Cox proportional hazards regression models 
and presented as Kaplan–Meier estimates with hazard ratio 
(HR) and 95% confidence intervals (CI). Similarly to the first 
part of the study, only separate comparisons of each mainte-
nance arm with the observation control arm were performed 
All patients receiving pemetrexed were included in the effi-
cacy analysis for primary objective (PFS) and were consid-
ered assessable for toxicity from the time of their treatment 
by pemetrexed.
RESULTS
Patient Characteristics
From July 2006 through June 2009, 464 patients were 
enrolled at 51 institutions in France and randomized after 
four cycles of cisplatin-gemcitabine induction chemotherapy 
to observation (n = 155), gemcitabine (n = 154), or erlotinib 
(n = 155) maintenance treatment (Table 1). Figure 1 provides 
a flow diagram for patient throughout the post-hoc analysis. 
Only a few patients received a second line different from that 
imposed by the protocol. Seventy-eight percent (360 out of 
464) of patients included in IFCT–GFPC 0502 study received 
TABLE 1.  Patients Characteristics
Characteristic
Arm A (Observation) Arm B (Gemcitabine) Arm C (Erlotinib)
p Value
(n = 130) (n = 114) (n = 116)
Number of Patients (%) Number of Patients (%) Number of Patients (%)
Age, yrs
0.229 Median 58.95 57.50 56.25
 Range 36.50–72.10 29.20–70 35.50–71.20
Sex
0.863 Male 94 72.3 80 70.2 85 73.3
 Female 36 27.7 34 29.8 31 26.7
Smoking status
0.143 Never-smoker 8 6.2 14 12.3 15 12.9
 Former/current smoker 121 93.8 100 87.7 101 87.1
Stage of disease
0.972 IIIB 12 9.4 10 9.0 9 8.2
 IV 116 90.6 101 91.0 101 91.8
ECOG performance status
0.480
 0 57 44.2 47 41.6 41 36.0
 1 70 54.3 62 54.9 68 59.6
 2 1 0.8 4 3.5 4 3.5
Histologic types
0.546
 Squamous cell carcinoma 28 21.5 23 20.2 18 15.5
 Adenocarcinoma 82 63.1 77 67.5 76 65.5
 Other: NSCLC, NOS 20 15.3 14 12.2 22 19.0
Response after CT induction
0.963 Stable disease 56 43.1 51 44.7 50 43.1
 CR/PR 74 56.9 63 55.3 66 56.9
CR, complete response; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; NSCLC, non–small-cell lung cancer; PR, partial response.
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pemetrexed as second-line treatment, with 83%, 74%, and 
75% in observation arm, gemcitabine arm, and erlotinib arm, 
respectively (χ2 test, p = 0.0070). The baseline characteris-
tics of this second-line pemetrexed population (Table 1) were 
representative of the entire population of the study (Table 2). 
The median age for the population treated with pemetrexed 
was 57.7 years (ranges 29–72 years). The study groups were 
well balanced in terms of prognostic factors and other base-
line characteristics (Table 1). Most patients were male and 
three-fifths had an Eastern Cooperative Oncology Group per-
formance status of 1. Most patients had a history of smoking 
and nearly 66% of patients had non-squamous cell histology; 
the proportion of patients with squamous-cell carcinoma was 
similar in the three arms.
Response to pemetrexed and PFS
The median number of delivered pemetrexed cycles 
was three, with no difference between the three arms 
(Kruskal–Wallis test, p = 0.659) (Table 3). Dose reduc-
tions of pemetrexed were mainly caused by neutropenia and 
thrombocytopenia, without difference between the three arms. 
Two hundred twenty-nine patients (63.4% of patients receiv-
ing pemetrexed) were evaluable for response. There was no 
significant difference in terms of objective responses and 
disease control rate across the three arms (Fisher’s exact test 
p = 0.446) (Table 3). For non-squamous carcinoma, response 
assessment was available for 199 patients (65% of non-squa-
mous patients treated with pemetrexed), with a non significant 
trend toward a better response rate for observation and erlo-
tinib arms, but without difference for the disease control rate 
between the three arms (Fisher’s exact test p = 0.207) (Table 3).
PFS from the start of second-line pemetrexed treatment 
for patients randomly assigned to gemcitabine did not dif-
fer significantly from that of patients in the observation arm 
(median PFS 4.2 versus 3.9 months; HR [95% CI] 0.81 [0.62–
1.06], p = 0.124) (Fig. 2). Similarly, the PFS for erlotinib arm 
was not different from that of observation arm (median PFS 
4.2 versus 3.9 months; HR 0.83 [0.64–1.09], p = 0.174) (Fig. 
2A). When analysis was restricted to non-squamous patients, 
PFS remained similar for gemcitabine and observation arms 
(4.1 versus 4.2 months) and for erlotinib and observation arms 
(4.2 versus 4.2 months) (Fig. 2B).
Subsequent Treatments
Data on further treatments (third-line chemotherapy) 
was available for 293 of 360 patients, with 108, 93, and 92 
in control, gemcitabine, and erlotinib arms, respectively 
(Table 4). Erlotinib was the most frequently used third-line 
drug in the observation and gemcitabine arms. Docetaxel was 
the most prescribed systemic chemotherapy when progres-
sion occurred after pemetrexed (10.2%, 21.2%, and 48.9% 
for control, gemcitabine, and erlotinib arms, respectively). 
Approximately 20% of patients in each arm were not treated 
with a third-line drug and only received best supportive care.
OS From the Beginning of 
Second-Line Pemetrexed
OS did not statistically differ between gemcitabine arm 
and control arm (median OS 8.3 versus 7.5 months; HR = 
0.81 [0.61–1.07], p = 0.12), and between erlotinib arm and 
control arm (median OS 9.1 versus 7.5 months; HR = 0.80 
[0.61–1.05], p = 0.108) (Fig. 3). Analysis of OS restricted to 
FIGURE 1.  Patient disposition diagram. BSC, best supportive care; CT, chemotherapy. 
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patients with non-squamous carcinoma showed similar results 
(Fig. 3A,B)
Safety of Second-Line Pemetrexed
Two hundred sixty-nine patients (74.7%) reported an 
AE of any grade, with a similar distribution across the three 
arms (76.2%, 74.6%, and 73.3% in observation, gemcitabine, 
and erlotinib arms, respectively, χ2 test, p = 0.873) (Table 5). 
Grade 3 to 4 AEs were reported in 108 (30%) patients who 
received pemetrexed. Overall rates of grade 3 and 4 hema-
tologic and non-hematologic AEs in each arm are shown in 
Table 5. Neutropenia was the most common AE in the three 
arms (13.1%, 19.3%, and 9.5% in observation, gemcitabine, 
and erlotinib arms, respectively) followed by thrombocy-
topenia and anemia. Non-hematologic AEs were grade 3 to 
4 fatigue (4.7%), pain (3.6%), and constitutional symptoms 
(3.1%). There was no grade 5 AE. Overall, the level of toxicity 
did not differ between the observation control arm and both 
maintenance arms.
DISCUSSION
IFCT–GFPC 0502 study showed that continuation 
maintenance with gemcitabine provides a large PFS benefit 
(HR = 0.56) but with a limited impact on OS. Similarly, meta-
analysis of continuation maintenance studies demonstrated a 
consistent PFS benefit without significant impact on OS.21,22 
However, these meta-analyses did not include the Paramount 
study which is the only study showing that PFS benefit from 
continuation maintenance with pemetrexed did result in an OS 
benefit. One hypothesis to explain these results is that there 
could be a negative interaction between continuous exposure 
of tumor cells to chemotherapy during maintenance treatment, 
leading to cross-resistance and ineffectiveness of subsequent 
treatments, especially second-line chemotherapy; moreover, 
TABLE 2.  Comparison between Baseline Characteristics of Patients Treated with Pemetrexed as Second-Line Therapy and 
Those of the Entire Population of the Study
Arm A (Oservation) Arm B (Gemcitabine) Arm C (Erlotinib)
Characteristic
Entire 
Population of 
the 0502 Study
Second-line  
Pemetrexed  
Population
Entire  
Population of  
the 0502 Study
Second-line  
Pemetrexed  
Population
Entire 
Population of 
the 0502 Study
Second-line 
Pemetrexed 
Population
(n = 155) (n = 130) (n = 154) (n = 114) (n = 155) (n = 116)
Number of 
Patients %
Number of 
Patients %
Number of 
Patients %
Number of 
Patients %
Number of 
Patients %
Number of 
Patients %
Age, yrs
 Median 59.8 58.95 57.9 57.50 56.4 56.25
 Range 37.0–72.0 36.50–72.10 29.0–71.0 29.20–70 36.0–71.0 35.50–71.20
Sex
 Male 113 72.9 94 72.3 113 73.4 80 70.2 113 72.9 85 73.3
 Female 42 27.1 36 27.7 41 26.6 34 29.8 42 27.1 31 26.7
Smoking status
 Never-smoker 12 7.7 8 6.2 17 11.0 14 12.3 17 11.0 15 12.9
 Former/current 
smoker
143 92.3 121 93.8 137 89.0 100 87.7 138 89.0 101 87.1
Stage of disease
 IIIB 14 9.2 12 9.4 14 9.3 10 8.7 11 7.4 9 7.8
 IV 139 90.8 116 89.2 137 90.7 101 88.5 137 92.6 101 87.0
 Unknown 2 1.3 2 1.4 3 1.9 3 2.6 7 4.5 6 5.2
ECOG performance status
 0 68 44.2 57 44.2 61 40.1 47 41.6 58 37.9 41 36.0
 1 81 52.6 70 54.3 82 53.9 62 54.9 85 55.6 68 59.6
 2 4 2.6 1 0.8 7 4.6 4 3.5 8 5.2 4 3.5
Histologic types
 Squamous cell 
carcinoma
30 19.3 28 21.5 34 22.1 23 20.2 27 17.4 18 15.5
 Adenocarcinoma 103 66.5 82 63.1 101 65.6 77 67.5 97 62.6 76 65.5
 Other: NSCLC, 
NOS
22 14.2 20 15.3 19 12.3 14 12.2 31 20.0 22 19.0
Response after CT induction
 Stable disease 73 47.1 56 43.1 73 47.1 51 44.7 73 52.9 50 43.1
 CR/PR 82 52.9 74 56.9 81 52.6 63 55.3 82 47.1 66 56.9
CR, complete response; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; NSCLC, non–small-cell lung cancer; PR, partial response.
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TABLE 3.  Duration and Effectiveness of Pemetrexed Second-Line Therapy
Arm A (N = 130) (%) Arm B (N = 114) (%) Arm C (N = 116) (%)
All Patients  
(N = 130)
Non-Squamous 
Patients (N = 102)
All Patients  
(N = 114)
Non-Squamous 
Patients (N = 91)
All Patients  
(N = 116)
Non-Squamous  
Patients (N = 98)
Median number  
Of cycles (range)
3 (1–18) 3 (1–40) 3 (1–15)
Response to second-line pemetrexed
Number evaluable  
patients (%)
89 (68.5) 70 (68.6) 67 (58.7) 57 (62.6) 73 (62.9) 62 (63.3)
CR (%) [95% CI] 0 (0.0) [0.0–4.1] 0 (0.0) [0.0–5.1] 0 (0.0) [0.0–5.4] 0 (0.0) [0.0–6.3] 1 (1.4) [0.0–7.4] 1 (1.6) [0.0–8.7]
PR (%) [95% CI] 13 (14.6) [8.0–23.7] 13 (18.6) [10.3–29.7] 4 (6.0) [1.7–14.6] 4 (7.0) [2.0–17.0] 9 (12.3) [5.8–22.1] 9 (14.5) [6.9–25.8]
SD (%) [95% CI] 39 (43.8) [33.3–54.8] 33 (47.1) [35.1–59.5] 33 (49.3) [36.9–61.8] 30 (50.9) [28.5–51.9] 29 (39.7) [28.5–51.9] 23 (37.1) [25.2–50.3]
PD (%) [95% CI] 37 (41.6) [31.2–52.5] 24 (34.3) [23.4–46.6] 30 (44.8) [32.6–57.4] 24 (42.1) [34.8–58.6] 34 (46.6) [34.8–58.6] 29 (46.8) [34.0–59.9]
CI, confidence intervals; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
Median number of cycles: Kruskal–Wallis p = 0.659. Response for all patients: Fisher’s exact p = 0.446; response for non-squamous patients: Fisher’s exact p= 0.207.
FIGURE 2. A, Progression-free sur-
vival from the beginning of peme-
trexed second-line therapy for patients 
treated with gemcitabine maintenance 
versus observation and for patients 
treated with erlotinib maintenance 
versus observation. B, Progression-free 
survival from the beginning of peme-
trexed second-line therapy for patients 
with non-squamous-cell carcinoma.
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maintenance with cytotoxic chemotherapy could increase 
the toxicity of subsequent second-line treatment precluding 
complete administration of treatment. The IFCT–GFPC 0502 
study including a pre-defined and similar second-line therapy 
in observation arm and both maintenance arms provided a 
unique opportunity to study the effectiveness and tolerance 
of second-line chemotherapy according to either a treatment-
free interval after induction chemotherapy or a maintenance 
treatment and to the kind of maintenance treatment, i.e., 
continuation maintenance with chemotherapy or maintenance 
with erlotinib. There was no strong preclinical or clinical 
data to support the hypothesis of cross-resistance between 
gemcitabine and pemetrexed. Phase II data exploring the 
combination of gemcitabine and pemetrexed suggest that the 
schedule with pemetrexed followed by gemcitabine was more 
effective and less toxic than the opposite schedule.23–26
There was a very high proportion of patients receiv-
ing a second-line treatment (226 of 293 patients, 77%), both 
in the control arm and in maintenance arms. This is much 
higher than in other maintenance trials10–15,27 and in clinical 
practice,28,29 with only a range of 51 to 63% of patients able 
to receive approved second-line treatment after maintenance 
therapy and of 58 to 67% after a treatment-free interval.13,14,30
The reasons were twofold: the good tolerance profile of 
pemetrexed as second-line agent; the compliance of investiga-
tors to the protocol with a large majority of patients receiving 
predefined pemetrexed as second-line treatment. The propor-
tion of patients undergoing a second line was 83% for the 
observation arm and approximately 74.5% for both mainte-
nance arms. If we include other drugs used in second-line, this 
proportion reach 94.5% in observation arm and 83% in both 
maintenance arms. Even if maintenance therapy after induc-
tion chemotherapy can reduce access to second-line treatment 
and therefore the translation of the PFS benefit into an OS 
gain, it does without any negative impact on OS as shown in 
the OS analysis of our study11 and in Paramount trial in which 
maintenance with pemetrexed provides a significant survival 
benefit despite of a lower proportion of patients receiving a 
second-line treatment.15 Maintenance therapy in advanced 
NSCLC is a strategy that capitalizes on the benefits of the first 
line, precisely because the effectiveness of the second line 
remains very modest in advanced NSCLC.
Median PFS from the beginning of pemetrexed second-
line therapy was 3.9 months in the observation arm and 4.2 
months for both erlotinib and gemcitabine maintenance arms, 
without any statistical difference for each maintenance arm 
compared with control observation arm. The PFS was higher 
than that found in other second-line studies in NSCLC.31–34 
For example, PFS obtained with pemetrexed was 2.9 months 
in the pivotal study comparing pemetrexed with docetaxel35 
and PFS of second-line treatment was 11.7 weeks in the meta-
analysis of Di Maio et al.31–34 Patients randomized in the main-
tenance phase of this study were selected patients, with either 
stable or responsive disease after induction chemotherapy. 
These patients represent a subgroup of patients with better 
prognosis, more likely to be controlled in the second line com-
pared with trials that include all patients, notably patients with 
disease progression during the first line treatment.36
Efficacy of second-line pemetrexed appears comparable 
with or without previous maintenance therapy, and whatever 
kind of maintenance, gemcitabine continuation maintenance 
or switch maintenance with erlotinib. The median number of 
delivered cycles of treatment was the same in all three arms, 
disease control rate were similar and PFS from the beginning 
of second-line pemetrexed did not differ between the three 
arms. Regarding the response rate, a lower rate of objective 
response was observed in gemcitabine arm than in both other 
but without impact on PFS. The analysis did not change when 
restricted to non-squamous patients. These results are valid for 
both the gemcitabine-pemetrexed and erlotinib-pemetrexed 
sequences but not necessarily applicable to sequences with 
other drugs. Nevertheless, the positive Paramount results 
for OS suggest that indeed continuation maintenance with 
pemetrexed does not impair effectiveness of subsequent 
treatments.
Nearly three-quarters of patients reported AEs, includ-
ing 30% of grade 3 to 4 toxicity (NCI-CTCAE). Patients 
previously exposed to cytotoxic drugs were more likely to 
have hematological AEs with second-line chemotherapy than 
patients experiencing a treatment-free interval after induction 
chemotherapy or treated with a non-cytotoxic maintenance 
drug like erlotinib. Neutropenia was the most frequently 
reported AE with a non-statistically significant increased rate 
in the gemcitabine arm compared with observation or erlotinib 
arms (19% versus 9.5% versus 13.5%, respectively). This rate 
of neutropenia was higher than that found in studies of sec-
ond-line pemetrexed, 13.5% (for the three arms) versus 4% 
to 5%.32,33 Other AEs were comparable to data from the litera-
ture. However, occurrence of neutropenia in the gemcitabine 
arm did not result in a higher rate of febrile neutropenia or 
infection, with 2.8% in all three arms and no treatment-related 
death. Moreover, the fact that the median number of delivered 
cycles was the same with or without previous maintenance 
also suggests that there is no cumulative toxicity due to main-
tenance treatment preventing administration of second-line 
chemotherapy.
Nevertheless, the limitations of this study imply that 
its results must be taken with caution. It is an exploratory 
TABLE 4.  Summary of Further Treatment Received by 
Patients
Arm A  
(Observation)  
(n = 108)
Arm B  
(Gemcitabine)  
(n = 93)
 Arm C  
(Erlotinib)  
(n = 92)
Number of  
Patients %
Number of  
Patients %
Number of 
Patients %
All classes 88 81.5 74 79.6 67 72.8
BSC 20 18.5 19 20.4 25 27.2
Docetaxel 11 10.2 20 21.5 45 48.9
Paclitaxel 3 2.8 4 4.3 7 7.6
Erlotinib 68 63.0 49 52.7 3 3.3
Gemcitabine 4 3.7 0 0.0 7 7.6
Vinorelbine 2 1.9 1 1.0 2 2.2
Others clinical trials 0 0.0 0 0.0 3 3.3
BSC, best supportive care.
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post-hoc analysis, response evaluation was not available for 
all patients and PFS was assessed by investigators, without 
independent review. However, the lack of difference for PFS 
between the 3 arms strongly suggests that efficacy of second-
line pemetrexed was not decreased by previous maintenance 
treatment.
In conclusion, maintenance therapy with gemcitabine 
continuation or erlotinib does not seem to impair efficacy, nor 
to increase the toxicity of second-line pemetrexed compara-
tively to administration after a treatment-free interval.
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